After pumping the brakes on their Angelman syndrome study, Ultragenyx and GeneTx are back in the race
Eleven months after high doses of Ultragenyx and GeneTx’s Angelman syndrome candidate temporarily caused some patients to lose their ability to walk, the FDA is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
